

BIOCON BIOLOGICS ITALY S.R.L.**BALANCE SHEET AS AT MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2025</u>	<u>March 31, 2024</u>
ASSETS			
Current assets			
Financial assets			
(i) Trade receivables	1	312	15
(ii) Cash and cash equivalents	2	484	-
Other current assets	3	12	-
Total current assets		808	15
TOTAL		808	15
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	15	15
Other equity	5	19	-
Total equity		34	15
Current liabilities			
Financial liabilities			
Trade payables	6	607	-
Income-tax liability (net)		7	-
Provisions	7	7	-
Other current liabilities	8	153	-
Total current liabilities		774	-
TOTAL		808	15

BIOCON BIOLOGICS ITALY S.R.L.**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Year ended March 31, 2025</u>	<u>Period ended March 31, 2024</u>
Income			
Revenue from operations	9	546	-
Total revenue		<u>546</u>	<u>-</u>
Employee benefits expense	10	377	-
Other expenses	11	143	-
Total expenses		<u>520</u>	<u>-</u>
Profit before tax		<u>26</u>	<u>-</u>
Tax expense			
Current tax		7	-
Deferred Tax		-	-
Total tax expense		<u>7</u>	<u>-</u>
Profit for the period		<u>19</u>	<u>-</u>

BIOCON BIOLOGICS ITALY S.R.L.**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	19	-
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Tax expense	7	-
Operating profit before working capital changes	26	-
Movements in working capital		
Decrease/(Increase) in trade receivables	(297)	(15)
Decrease/(Increase) in loans and advances and other assets	(12)	-
(Decrease)/Increase in trade payable, other liabilities and provisions	767	-
Cash generated/(utilised in) from operations	484	(15)
Direct taxes paid	-	-
Net cash flow generated/(utilised in) operating activities	484	(15)
II Cash flows from investing activities		
Net cash flow generated/(utilised) investing activities	-	-
III Cash flows from financing activities		
Proceeds from issue of equity shares	-	15
Net cash flow generated from financing activities	-	15
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	484	-
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the year	-	-
VII Cash and cash equivalents at the end of the year (IV + V + VI)	484	-
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	484	-
Total cash and cash equivalents [Refer note 2]	484	-

BIOCON BIOLOGICS ITALY S.R.L.**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>March 31, 2025</u>	<u>March 31, 2024</u>
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	312	15
	<u>312</u>	<u>15</u>
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	484	-
	<u>484</u>	<u>-</u>
3. Other current assets		
Other assets	12	-
	<u>12</u>	<u>-</u>
4. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
1 Equity share of EUR 15,000 each	15	15
	<u>15</u>	<u>15</u>
5. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	-	-
Profit for the year	19	-
Net surplus in the statement of profit and loss	<u>19</u>	<u>-</u>
Total other equity	<u>19</u>	<u>-</u>
6. Trade payables	<u>607</u>	<u>-</u>
7. Provisions		
Current		
Compensated absences	7	-
	<u>7</u>	<u>-</u>
8. Other liabilities		
Current liabilities		
Statutory liabilities	153	-
	<u>153</u>	<u>-</u>

BIOCON BIOLOGICS ITALY S.R.L.**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
9. Revenue from operations		
Sale of Services		
Support service cross charge to Group Companies	546	-
	546	-
10. Employee benefits expense		
Salaries, wages and bonus	377	-
	377	-
11. Other expenses		
Rates and taxes	6	-
Rent	4	-
Legal and professional fees	51	-
Travelling and conveyance	50	-
Sales promotion expenses	12	-
Printing and stationery	16	-
Miscellaneous expenses	4	-
	143	-